Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796131 | 0.84 | MEN1 (0.74) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL3943376 | 0.82 | MEN1 (0.62) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL31503950 | 0.81 | KMT2A (0.60) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL8503181 | 0.81 | KMT2A (0.60) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL13545245 | 0.81 | HCAR3 (0.50) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL8503182 | 0.81 | KMT2A (0.60) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL18469873 | 0.81 | KMT2A (0.60) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL5528679 | 0.81 | GAA (0.65) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL1446574 | 0.81 | KMT2A (0.60) | GAACYP1A2KMT2AMEN1MAPT | |
| SCHEMBL9143702 | 0.80 | SMN1; SMN2 (0.63) | GAACYP1A2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533983-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-2518066-B1 | NOVEL ANTI-PLATELET AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-104910148-A | Aminotriazolopyridines and use thereof as kinase inhibitors | SIGNAL PHARM LLC | 2015-09-16 | — | — | CN | disclosed |
| CN-102203093-B | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2015-05-13 | — | — | CN | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| EP-1673355-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| EP-0601302-B1 | Hair dyeing composition containing 3-pyridinazo dyes and novel 3-pyridazo dyes | WELLA AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| US-5371086-A | Circulatory disorders side effect reduction | THE GREEN CROSS CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0601302-A1 | Hair dyeing composition containing 3-pyridinazo dyes and novel 3-pyridazo dyes | Wella Aktiengesellschaft (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5262415-A | FOR TREATING DISEASES OF THE CIRCULATORY SYSTEM | THE GREEN CROSS CORPORATION (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0503627-A1 | Aminopyridine compounds | THE GREEN CROSS CORPORATION (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | F12, TBXA2R, F11 | GAA 4444/4885CYP1A2 850/4885KMT2A 3462/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | GAA 3490/4885CYP1A2 654/4885KMT2A 569/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | GAA 3939/4885CYP1A2 989/4885KMT2A 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.